αMT

Closure of psx:substance/amt/claim/7b0fe41e-cd1a-428e-8e48-7812bfa3d1a3: 55 upstream, 48 downstream.

psx:substance/amt/claim/7b0fe41e-cd1a-428e-8e48-7812bfa3d1a3
├─ used  src/doi:10.1007/s00213-021-05876-x  Serotonin toxicity of serotonergic psychedelics
  ├─ informed_by  claim/187c1c41-1a5f-4fd3-b9de-ea70975b152c  Claim in safety — supported
  ├─ informed_by  claim/f97570f5-ca7f-4341-8c43-28827252248c  Claim in safety — inconclusive  working
  ├─ informed_by  claim/8b517927-1153-45d9-a641-ca3b3c20f4c1  Claim in safety — supported
  ├─ informed_by  claim/94ef6788-8487-4860-b44b-9cd4291c2320  Claim in safety — supported
  ├─ informed_by  claim/8b2c2b3d-014b-4697-a519-3d50f9cd3202  Claim in safety — inconclusive  working
  ├─ informed_by  claim/1d5481c1-e81c-423b-8a29-cd871c268192  Claim in safety — supported
  ├─ informed_by  claim/ecbb4d75-bb8d-42ad-b756-b5f3bc7da519  Claim in safety — supported
  ├─ informed_by  claim/7b758846-e4d2-428c-bf66-0f456a48cd6e  Claim in safety — inconclusive  working
  ├─ informed_by  claim/bc4a22ec-4009-46b5-819a-3298d3022a09  Claim in safety — partially_supported
  ├─ informed_by  claim/5fa1a6b4-9da2-4b8a-8f61-c5438e938ca4  Claim in safety — supported
  ├─ informed_by  claim/9d0be216-0f0c-4a40-a264-88e2f059751c  Claim in safety — supported
  ├─ informed_by  claim/8c774afa-5b04-4340-b20a-210c04c1a045  Claim in safety — partially_supported
  ├─ informed_by  claim/5e3c02ae-da98-49f7-9206-ae67027acf63  Claim in safety — supported
  ├─ informed_by  claim/8926e4e3-54f4-4bd3-b336-0ff7ebb869f0  Claim in safety — supported
    ├─ used  src/url:20cb97e3473fcc7c  Alpha-methyltryptamine (Indopan) - NCATS Inxight Drugs
    ├─ used  src/pmid:12678045  Schedules of controlled substances: temporary placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I. Final rule.
    ├─ used  src/doi:10.1016/j.toxlet.2017.03.007  In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks.
    ├─ used  src/doi:10.1016/j.neures.2025.04.006  A systematic study of changes in monoamine neurotransmitters in the rat brain following acute administration of alpha-methyltryptamine (AMT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT).
    ├─ used  src/doi:10.1097/FBP.0000000000000841
    ├─ used  src/doi:10.1016/j.expneurol.2021.113638  New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review.
    ├─ used  src/doi:10.1021/acschemneuro.2c00170  Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
    ├─ used  src/doi:10.1016/j.bbr.2018.07.020  5-Methoxy-alpha-methyltryptamine (5-MeO-AMT), a tryptamine derivative, induces head-twitch responses in mice through the activation of serotonin receptor 2a in the prefrontal cortex.
    ├─ used  src/url:3c1fc77ba0385127  AMT Drug Information - DrugWise
    ├─ used  src/doi:10.1007/s00204-015-1513-x  The hallucinogenic world of tryptamines: an updated review.
    ├─ used  src/doi:10.2174/1570159X13666141210222409
    ├─ used  src/pmid:16105268  Fatality due to acute alpha-methyltryptamine intoxication.
    ├─ used  src/pmid:15455477  Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.
    ├─ used  src/url:c29bc5afd23f85d7  Legal Status of Alpha-methyltryptamine - Multiple Jurisdictions
    ├─ used  src/doi:10.1021/acschemneuro.5c00468  Dual Modulation of 5-HT2A Receptors and SERT by α-Ethyltryptamine and Its Optical Isomers.
    ├─ used  src/url:3ad72d5c592d8337  Release.org.uk - AMT Drug Information
    ├─ used  src/pmid:3091132  The effects of monoamine oxidase inhibitors on the ejaculatory response induced by 5-methoxy-N,N-dimethyltryptamine in the rat.
    ├─ used  src/doi:10.1007/s00204-020-02693-7  Designer drugs: mechanism of action and adverse effects
    ├─ used  src/doi:10.3390/metabo13010092  Alpha-methyltryptamine (alpha-MT) Metabolite Profiling in Human Hepatocyte Incubations and Postmortem Urine and Blood
    ├─ used  src/doi:10.1007/s00414-024-03236-w  Alpha-methyltryptamine and 5-(2-methylaminopropyl)-benzofuran (5-MAPB) fatal co-intoxication: case report and review of literature
    ├─ used  src/doi:10.3109/15563650.2014.885983  Patterns of presentation and clinical toxicity after reported use of alpha methyltryptamine in the United Kingdom. A report from the UK National Poisons Information Service.
    ├─ derived_from  gen/fa205cf9-0ea6-4773-8b45-a7f571ae0dd9  Generation — pipeline-v5
    ├─ generated_by  pub/793ed85a-cf09-4c5b-a475-4376fad1f033  Publication — backfill
      ├─ used  search/3cef03e3-4c35-4c50-bfb3-5ca4b9244b2f  Searched PubChem for "alpha-methyltryptamine"
      ├─ used  search/9836f18e-d64d-4a8d-869c-73767adeb3b3  Searched PubMed for "alpha-methyltryptamine AMT pharmacology"
      ├─ used  search/18269691-ab08-4ecd-b8c7-f30cf5682135  Searched PubMed for "alpha-methyltryptamine monoamine releasing serotonin toxicity"
      ├─ used  search/44039467-5906-40d2-95a9-60a7aed1acc7  Searched OpenAlex for "alpha-methyltryptamine AMT psychedelic pharmacology"
      ├─ used  search/9aae4ea6-eebf-4169-8711-30b593a84b3d  Searched PubMed for "alpha-methyltryptamine case report death fatality overdose"
      ├─ used  search/4d713a48-cfc1-4e10-b4bc-83c5d1fb14f3  Searched ClinicalTrials.gov for "alpha-methyltryptamine AMT tryptamine"
      ├─ used  search/89348684-355b-46b3-a5d6-99e57d451d52  Searched PubMed for "AMT tryptamine forensic analytical detection blood urine"
      ├─ used  search/74ab702b-4fa8-4e80-a956-1c213c0eb4d4  Searched PubMed for "Dual Modulation 5-HT2A SERT alpha-ethyltryptamine optical isomers"
      ├─ used  search/a6833ac6-4cb3-48f1-a0ab-97ceeaccf8fa  Searched WebSearch for "alpha-methyltryptamine AMT Indopan Soviet antidepressant history synthesis 1960s"
      ├─ used  search/45713db1-f206-46c7-bc4f-e8681af37d35  Searched WebSearch for "alpha-methyltryptamine AMT DEA Schedule I scheduling date UK legal status"
      ├─ used  search/9b2a7a6c-e51b-41f6-916f-984b65b65a7f  Searched NCATS Inxight Drugs
      ├─ used  search/905d5875-e0d5-4752-b39c-649aab1ca235  Searched DrugWise
      ├─ used  search/b6315c09-59ad-493a-8243-34df7c8493bf  Searched ClinicalTrials.gov for "NCT04053582"
      ├─ used  search/2c8902b6-9208-4d05-b7a9-7d5579fd4d22  Searched PubMed for "alpha-methyltryptamine metabolite profiling human hepatocyte postmortem urine blood"
      ├─ used  search/f37270cc-6c57-43ab-a1fc-08d272e4c2f1  Searched PubMed for "hallucinogen LSD tolerance cross-tolerance 5-HT2A receptor mechanism downregulation"
      ├─ used  search/7c1c95ff-5690-4031-926e-c517eff30beb  Searched WebSearch for "alpha-methyltryptamine AMT legal status Australia Canada Germany Japan controlled substance"
      └─ used  search/7fcacc49-c0df-4f8c-87a3-e331a1b5e0a6  Searched Multiple for "AMT pharmacological mechanisms cross-reference"
├─ informed_by  section/safety.full@1
  ├─ used  version/1  Revision 1
  ├─ used  claim/b2574038-f3c5-45f8-ba49-fef7b2eb59c6  Claim in comparative-pharmacology — inconclusive  working
  ├─ used  claim/fe3989e4-efec-44b4-a1bd-3ec963143f48  Claim in safety — inconclusive  working
  ├─ used  claim/b1027aaf-b43e-4ba0-b44b-12f2b0656bb5  Claim in safety — inconclusive  working
  ├─ used  claim/f3f14220-e363-4212-8d51-8b831891ce8c  Claim in safety — supported
  ├─ used  claim/561544d1-1b40-444d-8463-d32fabb60724  Claim in safety — inconclusive  working
  ├─ used  claim/42224581-e791-4374-b584-96cda2c9201c  Claim in safety — supported
    ├─ derived_from  issue/notice@76ddbaed5b37  Issued notice
    ├─ derived_from  issue/info_card@46bc1bb853c0  Issued info_card
    ├─ derived_from  issue/emergency@3f0909c25c71  Issued emergency
    ├─ derived_from  issue/notice@a5727d1128c1  Issued notice
    ├─ derived_from  issue/info_card@edd9e6b4fbff  Issued info_card
    ├─ derived_from  issue/emergency@c15c760aabf6  Issued emergency
    ├─ informed_by  section/comparative-pharmacology.full@1
      ├─ used  claim/669dac87-99c9-493c-a9db-7e384c9d1c5b  Claim in summary — supported
      ├─ used  claim/eaf33254-a000-4751-9707-ea3ebb024142  Claim in history — partially_supported
      ├─ used  claim/0914056a-a5bc-43ed-94cb-26f65f6994da  Claim in summary — partially_supported
      ├─ used  claim/b7e15848-0317-433a-a36d-35f77fc508e0  Claim in pharmacology — supported
      ├─ used  claim/6b63dbcb-9efc-4326-bb37-263d3f309ec5  Claim in pharmacokinetic-detail — partially_supported
      ├─ used  claim/a04c56e4-559a-4884-a789-4da63c2f2fdb  Claim in summary — partially_supported
      ├─ used  claim/bd0247ba-baad-4846-9e6e-0fc37a5f92ac  Claim in pharmacology — supported
      ├─ used  claim/3a7b820a-cc89-4ca2-9b00-5da84ae33326  Claim in neuroscience — supported
      ├─ used  claim/7fa5ba46-98f6-42fc-9c5d-1e64280dad5a  Claim in summary — supported
      ├─ used  claim/c63e4711-7a26-4467-8cc7-15e13361a3b6  Claim in pharmacology — supported
      ├─ used  claim/a7749afd-fff3-4fb4-a28b-d2fbd3fbe602  Claim in neuroscience — inconclusive  working
      ├─ used  claim/6ce627df-2f99-46ec-b055-f65fc6f7d4fe  Claim in neuroscience — supported
      ├─ used  claim/9100b923-7692-4241-816f-5e60d5444414  Claim in summary — supported
      ├─ used  claim/ac416b58-e772-417b-a2c8-1291efa4b545  Claim in summary — supported
      ├─ used  claim/db0f1d1a-c3a7-4c96-b5e2-b7afae35359f  Claim in summary — supported
      ├─ used  claim/650f1d01-739f-427f-8297-5edb5b99aca1  Claim in neuroscience — supported
      ├─ used  claim/6f730c06-7aab-4b75-8c4a-2ff1a68f8a3b  Claim in pharmacology — inconclusive  working
      ├─ used  claim/f2bf8b6a-1a74-4b53-94ff-663bf2cb019e  Claim in history — supported
      ├─ used  claim/71340da0-c9b1-4bae-9944-fee7dbf42f21  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/9c40d707-0f1a-41ff-9ef3-18600ccf8455  Claim in history — supported
      ├─ used  claim/ac8931c2-9592-4ee5-b3f6-fe670440da4b  Claim in history — supported
      ├─ used  claim/36375afe-9233-478c-8704-c978a7e3d10b  Claim in history — partially_supported
      ├─ used  claim/e31b36b3-bb42-4df1-aa5d-718175da24cd  Claim in clinical-evidence — partially_supported
      ├─ used  claim/ea701648-c981-4e78-a22a-937c592618cc  Claim in pharmacology — supported
      ├─ used  claim/f908de86-eec0-4ee2-9be6-717e35da37a5  Claim in chemistry — partially_supported
      ├─ used  claim/fe144654-607b-4337-a5de-29d4d7255c5c  Claim in receptor-pharmacology — partially_supported
      ├─ used  claim/93850a31-26ea-4224-bb79-6f333eff9c03  Claim in comparative-pharmacology — partially_supported
      ├─ used  claim/66a242f9-a9cc-4e18-b920-43b0e5967191  Claim in neuroscience — supported
      ├─ used  claim/418427c4-f4cd-438d-923b-f1ee7eb2468a  Claim in pharmacology — supported
      ├─ used  claim/323a5799-a2f4-49c5-a891-e269509455d7  Claim in pharmacology — supported
      ├─ used  claim/223a26f6-954e-4f37-87c0-057c5997b57e  Claim in comparative-pharmacology — supported
      ├─ used  claim/3e988bd4-e133-45d4-9982-958b8c84e390  Claim in pharmacology — supported
      └─ used  claim/2d7d5a8e-f271-40c8-8805-8ade7aa8d113  Claim in pharmacokinetic-detail — supported
… closure truncated at 200 nodes

indented by distance from this node, not by parentage